The proposed C-TIRADS-guided framework can localize thyroid nodules, classify guideline-defined ultrasound features, and provide standardized malignancy risk stratification and may assist physicians in thyroid ultrasound interpretation.
Abstract
Background Thyroid nodules refer to discrete lesions within the thyroid gland, caused by abnormal proliferation of thyroid cells and local growth. Thyroid ultrasound imaging is a non-invasive, widely used technique primarily employed to assess the benign or malignant nature of nodules, the extent of invasion into adjacent tissues, and lymph node metastasis. Early ultrasound diagnosis can help reduce the incidence of thyroid cancer. However, the diagnostic results from ultrasound examinations are often subjective, labor-intensive, and highly dependent on the clinical experience of the ultrasound physician. Methods We developed a C-TIRADS-guided computer-aided diagnostic framework consisting of a nodule detection module, a C-TIRADS feature classification module, and a rule-based risk scoring module. Thyroid nodules were first localized using the detection network and then classified according to key C-TIRADS ultrasound features, including composition, echogenicity, margin, shape, and echogenic foci. The predicted feature scores were aggregated to determine the benign or malignant risk category. The model was trained using task-specific datasets and clinically validated on an independent cohort of 303 thyroid nodules/images from 284 patients. Results In the independent clinical validation set, the AI model achieved an overall accuracy of 0.862 [95% CI, 0.822–0.901]. Physician accuracy was 0.705 [95% CI, 0.657–0.756] without AI assistance and increased to 0.845 [95% CI, 0.802–0.884] with AI assistance. These findings suggest the potential value of the proposed system as a C-TIRADS-guided decision-support tool. Conclusion The proposed C-TIRADS-guided framework can localize thyroid nodules, classify guideline-defined ultrasound features, and provide standardized malignancy risk stratification. The model may assist physicians in thyroid ultrasound interpretation; however, larger blinded multicenter studies are required before routine clinical application.
The AI-UADS demonstrates good diagnostic performance in differentiating BTNs and MTNs, and can serve as an effective auxiliary tool for ultrasonographers, showing particular advantages in diagnosing nodules with a maximum diameter, located in the left lobe, far from the capsule, and in patients without HT.
A bilinear convolutional neural network model named THBCNN is proposed, enabling the model to make more accurate judgments on the benign and malignant nature of thyroid nodules across multiple feature dimensions.
Jun-Feng Wang, He-Fan Yao, Demin Kong et al.· Journal of imaging informati...· 0 citations
The application of artificial intelligence is not limited to diagnosis and is expanding to the selection of follow-up intervals, automated detection of nodule growth, bronchoscopic navigation, surgical planning, and determination of treatment volumes in radiation therapy.
N. Nazarov· Journal of modern medicine· 0 citations
A two-stage deep learning-based model for automatic detection and classification of thyroid nodules in ultrasound images shows that segmentation with weak supervision along with classification using deep learning can provide efficient diagnosis of thyroid nodules even with minimal medical data annotation.
K. Subedi, Akash Yadav, Lochan Paudel· International Journal of Ele...· 0 citations
Vessel-suppressed images demonstrated high sensitivity for malignant pulmonary nodules, whereas CADe performance varied by nodule type and location, whereas CADe performance varied by nodule type and location.
Ariadne K. DeSimone, Kathryn A. Schulz, S. Byrne et al.· Journal of thoracic imaging· 0 citations
Objective To investigate the diagnostic value of a multimodal prediction model integrating thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), the Chinese Thyroid Imaging Reporting and Data System (C-TIRADS), and BRAF V600E mutation status, for evaluating the malignancy risk in Bethesda Category III thy...
Wei Yang, C. Xiong, Shuang-Shuang Dong et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.